None of the 29 investors followed here reported a position in TSHA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TSHA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 9, 2026 | Nagendran SukumarOfficer and Director | Sale at price 6.24 per share. | 200K | $1.25M |
| May 31, 2026 | Donenberg Phillip BrianDirector | Stock Award(Grant) at price 0.00 per share. | 21.3K | — |
| May 31, 2026 | Stalfort John ADirector | Stock Award(Grant) at price 0.00 per share. | 21.3K | — |
| May 31, 2026 | Sepp-Lorenzino LauraDirector | Stock Award(Grant) at price 0.00 per share. | 21.3K | — |
| May 31, 2026 | Long Alison SDirector | Stock Award(Grant) at price 0.00 per share. | 21.3K | — |
| Apr 9, 2026 | Nagendran SukumarPresident | Conversion of Exercise of derivative security at price 1.71 per share. | 19K | $32.53K |
| Apr 9, 2026 | Nagendran SukumarPresident | Sale at price 4.46 per share. | 200K | $892.00K |
| Feb 3, 2026 | Alam KamranChief Financial Officer | Sale at price 4.52 per share. | 1.7K | $7.48K |
| Jan 25, 2026 | Nolan Sean PatrickChief Executive Officer | Sale at price 4.61 - 4.75 per share. | 178.1K | $840.20K |
| Jan 25, 2026 | Nagendran SukumarOfficer and Director | Sale at price 4.61 - 4.75 per share. | 116K | $547.47K |
| Jan 25, 2026 | Alam KamranChief Financial Officer | Sale at price 4.61 - 4.75 per share. | 102.8K | $485.04K |
| Jan 11, 2026 | Nagendran SukumarOfficer and Director | Conversion of Exercise of derivative security at price 0.70 - 1.71 per share. | 200K | $229.44K |
| Jan 11, 2026 | Nolan Sean PatrickChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 1.01M | — |
| Jan 11, 2026 | Nagendran SukumarOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 427K | — |
| Jan 11, 2026 | Alam KamranChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 359K | — |
| Jan 11, 2026 | Nagendran SukumarOfficer and Director | Sale at price 4.71 per share. | 200K | $942.00K |
| Nov 30, 2025 | Nagendran SukumarOfficer and Director | Conversion of Exercise of derivative security at price 0.70 - 1.71 per share. | 370.2K | $562.04K |
| Nov 30, 2025 | Nagendran SukumarOfficer and Director | Sale at price 4.51 - 4.75 per share. | 370.2K | $1.70M |
| Sep 9, 2025 | Nagendran SukumarPresident | Conversion of Exercise of derivative security at price 0.70 per share. | 41.1K | $28.76K |
| Sep 9, 2025 | Nagendran SukumarPresident | Sale at price 3.23 per share. | 200K | $646.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -18.0 | 0.4 | -1.3 | 43.0 | -8.1 | 16.0 | -14.0 | -2.9 | -14.4 | -23.1 | −31.9% | ||
| 2025 | -13.3 | 6.7 | -13.1 | 39.6 | 39.7 | -14.8 | 18.2 | 7.0 | 12.0 | 51.7 | -4.4 | 16.0 | +217.9% |
| 2024 | -14.1 | 107.9 | -9.2 | -15.3 | 41.2 | -34.7 | -1.3 | 1.4 | -10.3 | -15.9 | 91.7 | -46.6 | −2.3% |
| 2023 | -27.4 | -38.4 | -21.0 | -2.9 | -9.8 | -5.4 | 1.8 | 375.5 | -1.2 | -25.9 | -24.8 | 0.6 | −21.7% |
| 2022 | -31.8 | -19.9 | 2.4 | -43.9 | -30.3 | 45.9 | 9.4 | -22.4 | -38.9 | -10.9 | 28.5 | 2.3 | −80.6% |
| 2021 | -2.0 | -1.6 | -20.7 | 27.1 | -12.8 | -5.8 | -18.4 | 15.0 | -6.3 | -16.0 | -17.0 | -10.2 | −56.1% |
| 2020 | -7.1 | 8.8 | 17.3 | +18.5% |
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Buy / hold / sell counts